InMed Historical Balance Sheet

INM Stock

USD 5.26 0.11 2.14%

Trend analysis of InMed Pharmaceuticals balance sheet accounts such as Total Stockholder Equity of 9.7 M or Property Plant And Equipment Net of 1.3 M provides information on InMed Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of InMed Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using InMed Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining InMed Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether InMed Pharmaceuticals is a good buy for the upcoming year.

InMed Pharmaceuticals Inventory

1.31 Million

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

About InMed Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of InMed Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. InMed Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of InMed Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which InMed currently owns. An asset can also be divided into two categories, current and non-current.

InMed Pharmaceuticals Balance Sheet Chart

At this time, InMed Pharmaceuticals' Common Stock Shares Outstanding is very stable compared to the past year. As of the 15th of December 2024, Short Term Investments is likely to grow to about 45.2 M, though Net Debt is likely to grow to (5.3 M).

Retained Earnings Non Current Assets Total Capital Stock

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Most accounts from InMed Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into InMed Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in InMed Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.At this time, InMed Pharmaceuticals' Common Stock Shares Outstanding is very stable compared to the past year. As of the 15th of December 2024, Short Term Investments is likely to grow to about 45.2 M, though Net Debt is likely to grow to (5.3 M).

	2021	2022	2023	2024 (projected)
Total Current Liabilities	3.3M	2.0M	2.0M	1.1M
Total Assets	12.8M	14.1M	11.8M	12.4M

Total Current Liabilities Total Assets

InMed Pharmaceuticals balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Short Long Term Debt Total	Other Current Liab	Current Deferred Revenue	Short Term Debt	Good Will
Total Assets		0.6	0.99	0.2	-0.93	-0.58	0.76	0.92	0.31	-0.11	0.92	0.4	0.34	0.38	0.67	-0.07	-0.26	-0.24	0.6	0.99	0.2	0.36	0.51	-0.33	0.43	0.09
Total Current Liabilities	0.6		0.47	0.35	-0.4	-0.8	0.8	0.45	0.58	-0.1	0.39	0.36	0.3	0.3	0.22	-0.32	-0.27	0.18	0.94	0.52	0.44	0.49	0.88	-0.76	0.76	0.18
Total Stockholder Equity	0.99	0.47		0.13	-0.96	-0.46	0.69	0.95	0.19	-0.1	0.96	0.33	0.26	0.32	0.68	-0.03	-0.25	-0.32	0.46	0.99	0.11	0.26	0.39	-0.24	0.33	0.08
Property Plant And Equipment Net	0.2	0.35	0.13		0.08	-0.32	0.28	-0.09	0.75	0.77	-0.05	0.69	0.49	0.45	0.27	0.07	-0.09	0.39	0.45	0.09	-0.09	0.32	0.17	-0.12	0.4	-0.73
Net Debt	-0.93	-0.4	-0.96	0.08		0.37	-0.63	-0.99	0.01	0.25	-0.98	-0.14	-0.13	-0.18	-0.56	0.13	0.21	0.43	-0.36	-0.97	-0.07	-0.14	-0.35	0.23	-0.19	-0.23
Retained Earnings	-0.58	-0.8	-0.46	-0.32	0.37		-0.52	-0.37	-0.75	0.32	-0.29	-0.72	-0.75	-0.76	-0.21	0.17	0.39	-0.41	-0.9	-0.49	-0.74	-0.81	-0.67	0.55	-0.8	-0.28
Accounts Payable	0.76	0.8	0.69	0.28	-0.63	-0.52		0.64	0.27	0.01	0.67	0.22	0.15	0.09	0.66	-0.18	-0.02	-0.33	0.75	0.74	0.04	0.29	0.86	-0.4	0.38	0.01
Cash	0.92	0.45	0.95	-0.09	-0.99	-0.37	0.64		-0.01	-0.25	0.98	0.11	0.09	0.15	0.53	-0.14	-0.22	-0.43	0.37	0.96	0.07	0.12	0.38	-0.27	0.23	0.28
Non Current Assets Total	0.31	0.58	0.19	0.75	0.01	-0.75	0.27	-0.01		0.23	-0.05	0.83	0.74	0.73	0.12	0.12	-0.31	0.67	0.73	0.17	0.59	0.76	0.33	-0.39	0.82	-0.24
Non Currrent Assets Other	-0.11	-0.1	-0.1	0.77	0.25	0.32	0.01	-0.25	0.23		-0.15	0.17	-0.09	-0.08	0.13	0.08	0.05	0.11	-0.12	-0.16	-0.6	-0.31	-0.2	0.1	-0.1	-0.91
Cash And Short Term Investments	0.92	0.39	0.96	-0.05	-0.98	-0.29	0.67	0.98	-0.05	-0.15		0.1	0.05	0.11	0.64	-0.1	-0.17	-0.5	0.32	0.97	-0.04	0.05	0.38	-0.19	0.16	0.18
Net Receivables	0.4	0.36	0.33	0.69	-0.14	-0.72	0.22	0.11	0.83	0.17	0.1		0.92	0.94	0.34	0.21	-0.35	0.47	0.56	0.29	0.42	0.73	0.22	-0.07	0.6	-0.22
Common Stock Shares Outstanding	0.34	0.3	0.26	0.49	-0.13	-0.75	0.15	0.09	0.74	-0.09	0.05	0.92		0.9	0.32	0.11	-0.12	0.45	0.56	0.24	0.53	0.86	0.19	0.04	0.49	-0.01
Short Term Investments	0.38	0.3	0.32	0.45	-0.18	-0.76	0.09	0.15	0.73	-0.08	0.11	0.94	0.9		0.17	0.16	-0.54	0.49	0.49	0.28	0.57	0.68	0.19	-0.14	0.61	0.01
Non Current Liabilities Total	0.67	0.22	0.68	0.27	-0.56	-0.21	0.66	0.53	0.12	0.13	0.64	0.34	0.32	0.17		0.13	0.28	-0.39	0.3	0.67	-0.16	0.3	0.34	0.24	0.02	-0.16
Inventory	-0.07	-0.32	-0.03	0.07	0.13	0.17	-0.18	-0.14	0.12	0.08	-0.1	0.21	0.11	0.16	0.13		-0.07	-0.14	-0.26	-0.09	0.1	0.16	-0.29	0.53	0.13	-0.08
Other Current Assets	-0.26	-0.27	-0.25	-0.09	0.21	0.39	-0.02	-0.22	-0.31	0.05	-0.17	-0.35	-0.12	-0.54	0.28	-0.07		-0.27	-0.17	-0.22	-0.35	0.03	-0.18	0.53	-0.54	-0.08
Other Stockholder Equity	-0.24	0.18	-0.32	0.39	0.43	-0.41	-0.33	-0.43	0.67	0.11	-0.5	0.47	0.45	0.49	-0.39	-0.14	-0.27		0.28	-0.34	0.55	0.45	-0.1	-0.4	0.53	-0.11
Total Liab	0.6	0.94	0.46	0.45	-0.36	-0.9	0.75	0.37	0.73	-0.12	0.32	0.56	0.56	0.49	0.3	-0.26	-0.17	0.28		0.5	0.53	0.71	0.82	-0.62	0.74	0.09
Total Current Assets	0.99	0.52	0.99	0.09	-0.97	-0.49	0.74	0.96	0.17	-0.16	0.97	0.29	0.24	0.28	0.67	-0.09	-0.22	-0.34	0.5		0.14	0.27	0.47	-0.29	0.33	0.14
Intangible Assets	0.2	0.44	0.11	-0.09	-0.07	-0.74	0.04	0.07	0.59	-0.6	-0.04	0.42	0.53	0.57	-0.16	0.1	-0.35	0.55	0.53	0.14		0.76	0.28	-0.43	0.74	0.53
Short Long Term Debt Total	0.36	0.49	0.26	0.32	-0.14	-0.81	0.29	0.12	0.76	-0.31	0.05	0.73	0.86	0.68	0.3	0.16	0.03	0.45	0.71	0.27	0.76		0.35	-0.12	0.65	0.22
Other Current Liab	0.51	0.88	0.39	0.17	-0.35	-0.67	0.86	0.38	0.33	-0.2	0.38	0.22	0.19	0.19	0.34	-0.29	-0.18	-0.1	0.82	0.47	0.28	0.35		-0.57	0.52	0.24
Current Deferred Revenue	-0.33	-0.76	-0.24	-0.12	0.23	0.55	-0.4	-0.27	-0.39	0.1	-0.19	-0.07	0.04	-0.14	0.24	0.53	0.53	-0.4	-0.62	-0.29	-0.43	-0.12	-0.57		-0.64	-0.15
Short Term Debt	0.43	0.76	0.33	0.4	-0.19	-0.8	0.38	0.23	0.82	-0.1	0.16	0.6	0.49	0.61	0.02	0.13	-0.54	0.53	0.74	0.33	0.74	0.65	0.52	-0.64		0.2
Good Will	0.09	0.18	0.08	-0.73	-0.23	-0.28	0.01	0.28	-0.24	-0.91	0.18	-0.22	-0.01	0.01	-0.16	-0.08	-0.08	-0.11	0.09	0.14	0.53	0.22	0.24	-0.15	0.2

Click cells to compare fundamentals

InMed Pharmaceuticals Account Relationship Matchups

InMed Pharmaceuticals balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	7.5M	9.8M	12.8M	14.1M	11.8M	12.4M
Total Current Liabilities	1.7M	2.2M	3.3M	2.0M	2.0M	1.1M
Total Stockholder Equity	5.6M	7.4M	9.1M	12.1M	9.2M	9.7M
Property Plant And Equipment Net	402.6K	326.6K	904.3K	723.4K	1.2M	1.3M
Net Debt	(5.5M)	(7.1M)	(5.4M)	(8.5M)	(5.6M)	(5.3M)
Retained Earnings	(56.0M)	(74.9M)	(93.5M)	(101.4M)	(109.1M)	(103.6M)
Accounts Payable	959.2K	775.1K	1.2M	544.2K	626.2K	615.9K
Cash	5.8M	7.4M	6.2M	8.9M	6.6M	3.4M
Non Current Assets Total	1.2M	1.4M	3.2M	2.8M	3.1M	3.3M
Cash And Short Term Investments	5.8M	7.4M	6.2M	8.9M	6.6M	3.9M
Net Receivables	45.2K	11.9K	88.0K	260.4K	352.8K	370.5K
Common Stock Shares Outstanding	208.8K	270K	560.8K	2.4M	7.6M	8.0M
Short Term Investments	42.3K	46.5K	44.8K	44.4M	43.1M	45.2M
Liabilities And Stockholders Equity	7.5M	9.8M	12.8M	14.1M	11.8M	12.4M
Non Current Liabilities Total	247.5K	189.3K	389.5K	16.0K	644.9K	677.1K
Inventory	(919.56)	(955.8M)	2.5M	1.6M	1.2M	1.3M
Other Current Assets	418.9K	956.8K	842.0K	(8.9B)	477.7K	501.6K
Other Stockholder Equity	(59.5M)	21.5M	31.7M	35.7M	35.4M	37.1M
Total Liab	1.9M	2.4M	3.7M	2.0M	2.6M	2.7M
Total Current Assets	6.3M	8.4M	9.6M	11.3M	8.7M	9.1M
Accumulated Other Comprehensive Income	59.6M	63.4M	70.8M	128.6K	147.9K	140.5K
Intangible Assets	799.3K	1.1M	2.1M	1.9M	1.8M	1.9M
Common Stock	50.2M	60.6M	70.7M	77.6M	82.8M	53.5M
Net Tangible Assets	6.5M	6.3M	7.0M	10.1M	9.1M	9.1M
Net Invested Capital	5.6M	7.4M	9.1M	12.1M	9.2M	8.4M
Net Working Capital	4.6M	6.2M	6.3M	9.3M	6.7M	7.1M
Property Plant Equipment	549.9K	326.6K	904.3K	723.4K	831.9K	873.5K
Capital Stock	50.2M	60.6M	70.7M	77.6M	82.8M	72.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:

How To Invest In InMed

Details

Is InMed Stock a good investment?

Details

What is InMed Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

230.4

Revenue Per Share

0.603

Quarterly Revenue Growth

(0.45)

Return On Assets

(0.39)

Return On Equity

(0.72)

The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

InMed Historical Balance Sheet

InMed Pharmaceuticals Inventory

1.31 Million

About InMed Balance Sheet Analysis

InMed Pharmaceuticals Balance Sheet Chart

Retained Earnings

Non Current Assets Total

Capital Stock

InMed Pharmaceuticals balance sheet Correlations

InMed Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

InMed Pharmaceuticals balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.98	Cash
Total Current Assets	+ 0.97	Cash And Short Term Investments
Cash And Short Term Investments	+ 0.96	Total Stockholder Equity

Cash	- 0.99	Net Debt
Cash And Short Term Investments	- 0.98	Net Debt
Total Current Assets	- 0.97	Net Debt
Net Debt	- 0.96	Total Stockholder Equity
Net Debt	- 0.93	Total Assets
Good Will	- 0.91	Non Currrent Assets Other